Skip NavigationSkip to Content

Antineoplastic Agents 360 - Synthesis and Cancer Cell Growth Inhibitory Studies of Dolastatin 15 Structural Modifications

  1. Author:
    Pettit, G. R.
    Flahive, E. J.
    Boyd, M. R.
    Bai, R. L.
    Hamel, E.
    Pettit, R. K.
    Schmidt, J. M.
    1. Year: 1998
  1. Journal: Anti-Cancer Drug Design
    1. 13
    2. 1
    3. Pages: 47-66
  2. Type of Article: Article
  1. Abstract:

    Dolastatin 15 (1), a potent antineoplastic constituent of the Indian Ocean shell-less mollusk Dolabella auricularia, was utilized as the lead substance for a series of structure-activity studies. The synthetic methods, in vitro evaluations against a variety of murine and human cancer cell lines, as well as a selection of bacteria and fungi, and inhibition of tubulin polymerization are described. Remarkably, all of the compounds studied, in which the C-terminal (S)-dolapyrrolidinone unit (Dpy) was replaced with a series of structurally diverse and more readily available amides, showed cancer cell growth inhibition activities generally quite comparable to those of the parent molecule (1). All analogues, however, were less potent than 1 as inhibitors of tubulin polymerization. The structurally modified peptides, like the parent compound, caused mitotic arrest in cultured cells, consistent with tubulin being the primary cellular target. The ability of dolastatin 15 and eight modifications or precursors thereof to inhibit the growth of a Gram-negative bacterium suggests that these compounds have an additional target distinct from tubulin. [References: 39]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel